Impact of Glycemic Control Strategies on the Progression of Diabetic Peripheral Neuropathy in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Cohort
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial demonstrated similar long-term clinical effectiveness of insulin-sensitizing (IS) versus insulin-providing (IP) treatments for type 2 diabetes on cardiovascular outcomes in a cohort with documented coronary artery disease. We evaluated the effects of randomized glycemic control strategy (IS vs. IP) on the prevalence and incidence of diabetic peripheral neuropathy (DPN). RESEARCH DESIGN AND METHODS: DPN (defined as Michigan Neuropathy Screening Instrument [MNSI] clinical examination score >2) was assessed at baseline and yearly for 4 years. DPN prevalence and incidence were compared by intention-to-treat modeling by logistic generalized estimating equation models for prevalence and Kaplan-Meier estimates and Cox regression models for incidence rates. RESULTS: Results are reported for 2,159 BARI 2D participants (70% males) with valid baseline and at least one follow-up MNSI score (mean age 62 ± 9 years, mean HbA1c 7.7 ± 1.6%, diabetes duration 10 ± 9 years). There were no differences in the prevalence of DPN between the IS and the IP groups throughout the 4 years of follow-up. In 1,075 BARI 2D participants with no DPN at baseline, the 4-year cumulative incidence rate of DPN was significantly lower in the IS (66%) than in the IP (72%) strategy group (P = 0.02), which remained significant after adjusting for the in-trial HbA1c (P = 0.04). In subgroup analyses, IS strategy had a greater benefit in men (hazard ratio 0.75 [99% CI 0.58–0.99], P < 0.01). CONCLUSIONS: Among patients with type 2 diabetes followed for up to 4 years during BARI 2D, a glycemic control therapy with IS significantly reduced the incidence of DPN compared with IP therapy and may add further benefit for men.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A combination of typical symptomatology and symmetrical distal sensory loss, or typical signs in the absence of symptoms, in a person with DM is highly suggestive of DPN and may not require additional evaluations or referral.547,565–567”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [566]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The diagnosis of DPN is principally a clinical one.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [566]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Xu, H., Barnes, G. T., Yang, Q., Tan, G., Yang, D., Chou, C. J., Sole, J., Nichols, A., Ross, J. S., Tartaglia, L. A., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200319451 · Cited by 6,760 · cited 1×
“In addition, the weight gain observedwith the IP treatment could have contributed to an increase in chronic inflammation and oxidative stress (36).”
BackgroundTesfaye, S., Boulton, A. J. M., Dyck, P. J., Freeman, R., Horowitz, M., Kempler, P., Lauria, G., Malik, R. A., Spallone, V., Vinik, A., et al. (2010) · Diabetes Care · doi:10.2337/dc10-1303 · Cited by 2,690
The global burden of diabetic foot disease
Boulton, A. J., Vileikyte, L., Ragnarson-Tennvall, G., & Apelqvist, J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67698-2 · Cited by 2,566 · cited 2×
“The 3-year survival rate in patients with DPN is 20% less than in age- and sex-matched diabetic patients without this complication (1,2).”
BackgroundA Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease
(2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805796 · Cited by 1,939
Feldman, E. L., Stevens, M. J., Thomas, P. K., Brown, M. B., Canal, N., & Greene, D. A. (1994) · Diabetes Care · doi:10.2337/diacare.17.11.1281 · Cited by 1,293 · cited 4×
“2 was shown to have the highest sensitivity and specificity of correctly classifying DPN (11,13); therefore, in the present analysis, DPN was defined as an MNSI clinical examination score of .”
BackgroundMethodInfluentialHaffner, S. M., Greenberg, A. S., Weston, W. M., Chen, H., Williams, K., & Freed, M. I. (2002) · Circulation · doi:10.1161/01.cir.0000025403.20953.23 · Cited by 884 · cited 1×
“In this respect, experimental and human data demonstrate that TZDs may reduce inflammatory responses through NF-kB blockade (20,21).”
BackgroundEnhanced glucose control for preventing and treating diabetic neuropathy
Callaghan, B. C., Little, A. A., Feldman, E. L., & Hughes, R. A. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007543.pub2 · Cited by 584
Cited by
Items 101–167 of 167
Aziz, N., Dash, B., Wal, P., Kumari, P., Joshi, P., & Wal, A. (2023) · Current Diabetes Reviews · doi:10.2174/0115733998242299231011181615 · Cited by 12
Wei, W., Li, L., Deng, L., Wang, Z., Dong, J., Lyu, X., Jia, T., Wang, L., Wang, H., Mao, H., et al. (2020) · Cell Transplantation · doi:10.1177/0963689720949258 · Cited by 9
Ankita, A., Štefaničková, J., Saxena, S., Nim, D. K., Ahmad, K., Mahdi, A. A., Kaur, A., Bhasker, S. K., Valášková, J., & Kružliak, P. (2019) · International Ophthalmology · doi:10.1007/s10792-018-01063-8 · Cited by 9
Diabetes and the Nervous System
Vinik, A. I., CASELLINI, C. M., & Neumann, S. A. (2020) · Endocrinology · doi:10.1007/978-3-030-36694-0_10 · Cited by 13
Prealbumin to fibrinogen ratio is closely associated with diabetic peripheral neuropathy
Zang, S., Shi, L., Zhao, J., Yang, M., Liu, J., & Ding, H. (2020) · Endocrine Connections · doi:10.1530/ec-20-0316 · Cited by 8
“The status of DPN may also lead to higher morbidity and mortality, which increases the financial burden of T2DM treatment (5, 6).”
BackgroundRicciardi, D., Galiero, R., Todisco, V., Tedeschi, G., Loffredo, G., Caturano, A., Rinaldi, L., Cirillo, G., & Sasso, F. C. (2024) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2024.20 · Cited by 8
Differential Impact of Metabolic Factors and Comorbidities on Peripheral Neuropathy
Ponirakis, G., Petropoulos, I. N., Gad, H., Abdulshakoor, S., Concepcion, J. M., Khalfalla, S. H., Elamin, I. S. A., AlZawqari, A. T. H., Elgassim, E., Baraka, A., et al. (2025) · Journal of the Peripheral Nervous System · doi:10.1111/jns.70004 · Cited by 7
Immunological mechanisms and therapeutic advances in diabetic neuropathy
Jiang, S., Zhang, L., Zhao, L., Lv, Y., Cheng, S., Liu, C., Xu, S., & Zhang, B. (2026) · Journal of Neurology · doi:10.1007/s00415-025-13594-z · Cited by 7
“Studies have shown that at least 50% of individuals with diabetes will eventually develop DN, which presents with a wide range of clinical manifestations [4].”
Prevention of Peripheral Distal Polyneuropathy in Patients with Diabetes: A Systematic Review
Carvajal-Moreno, L., Coheña‐Jiménez, M., García-Ventura, I., Pabón‐Carrasco, M., & Belloso, A. J. P. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11061723 · Cited by 8
“The remaining four studies were cohort studies from RCTs, [58,60], of which one was placebo-controlled.”
BackgroundMethodInfluentialStatin therapy and neuropathy in type 1 diabetes: A cross‐sectional study
Pasha, R., Kamath, A., Linn, Z., Kalteniece, A., Bashir, B., Schofield, J. D., Malik, R. A., Azmi, S., Ferdousi, M., & Soran, H. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16617 · Cited by 8
Peripheral and Autonomic Neuropathy in Diabetes
Pop‐Busui, R., Boulton, A. J. M., & Sosenko, J. M. (2018) · Cited by 12
Self-citationSabaghan, M., Ataee, S., Ataee, M., Tebyanian, M., Afrashteh, S., & Daneshi, N. (2023) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-022-01165-1 · Cited by 6
“Early recognition and appropriate management of neuropathy in patients can help to improve symptoms, reduce sequelae, and increase the quality of life and preventive foot care [11].”
BackgroundCost-Effective Offloading of Diabetic Foot Ulcer in a Resource-Crunch Setting: A Case Report
Tewari, J., Roy, S., Rana, A., & Tewari, A. (2023) · Cureus · doi:10.7759/cureus.51173 · Cited by 5
“The pursuit of euglycemic status as a therapeutic approach is supported by evidence indicating that glycemic control exerts a delaying influence on the onset and progression of diabetic retinopathy, nephropathy, and neuropathy in patients with insulin-dependent diabetes mellitus [9,10].”
BackgroundManagement of Diabetes Mellitus
Jenkins, A. J., SCOTT, E. S., Fulcher, J., Kilov, G., & Januszewski, A. S. (2018) · Contemporary cardiology · doi:10.1007/978-3-319-97622-8_7 · Cited by 6
Height is a risk factor for development of peripheral insensate neuropathy
Sujjay, J., Green, S. R., & Mohamed Kasim, A. (2019) · International Journal of Advances in Medicine · doi:10.18203/2349-3933.ijam20192253 · Cited by 4
Ponirakis, G., Al‐Janahi, I., Elgassim, E., Hussein, R., Petropoulos, I. N., Gad, H., Khan, A., Zaghloul, H. B., Siddique, M. A., Ali, H. A., et al. (2024) · Journal of the Peripheral Nervous System · doi:10.1111/jns.12664 · Cited by 5
Mondelli, M., Aretini, A., & Ginanneschi, F. (2021) · American Journal of Physical Medicine & Rehabilitation · doi:10.1097/phm.0000000000001769 · Cited by 4
Ziegler, D. (2020) · Der Diabetologe · doi:10.1007/s11428-020-00577-z · Cited by 4
Raghav, A., Singh, M. P., Jeong, G., Giri, R., Agarwal, S., & Kala, S. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1036220 · Cited by 4
Update 2014 zur diabetischen Neuropathie
Ziegler, D. (2014) · Der Diabetologe · doi:10.1007/s11428-014-1195-7 · Cited by 5
ATP-sensitive potassium channels in pain and analgesia
Lima, T. D. C., Santos, D. D. O., & Lotufo, C. M. D. C. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820589-1.00009-9 · Cited by 3
Approach to Painful Diabetic Peripheral Neuropathy
Lumpatki, S. B., Kavitha, K. V., Manohar, M., & Unnikrishnan, A. G. (2022) · Chronicle of Diabetes Research and Practice · doi:10.4103/cdrp.cdrp_4_22 · Cited by 3
Medical and socio-demographic determinants of depressive disorders in diabetic patients
Florek-Łuszczki, M., Choina, P., Kostrzewa-Zabłocka, E., Panasiuk, L., & Dziemidok, P. (2020) · Annals of Agricultural and Environmental Medicine · doi:10.26444/aaem/118529 · Cited by 5
“It is estimated that the risk of occurrence of neuropathy increases 10 years after the occurrence of diabetes in patients with both type 1 and 2 diabetes, and concerns 40–50% of those afflicted with this disease [5, 6, 7, 8, 9].”
BackgroundDetection of diabetic polyneuropathy in a family medicine clinic by using monofilament
Lakić, B., Petrović, V., Račić, M., & Stanetić, K. (2020) · Vojnosanitetski pregled · doi:10.2298/vsp200226053l · Cited by 3
“6 The epidemiological research found that prevalence of DPN in the world is greater than 50%, when adjusted for diabetes duration and age (18,19,20).”
BackgroundClinical Diagnosis of Diabetic Peripheral Neuropathy
Perkins, B. A., & Bril, V. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-15613-7_5 · Cited by 3
Self-citationDiabetes and the Nervous System
Vinik, A. I., CASELLINI, C. M., & Neuman, S. (2018) · Endocrinology · doi:10.1007/978-3-319-27316-7_10-1 · Cited by 2
Classical Therapies Versus Combined Therapies in Diabetic Neuropathy.
Rotaru, A., Târtea, E. A., & Iancău, M. (2020) · PubMed Central · doi:10.12865/chsj.46.02.04 · Cited by 2
Introductory Chapter: Diabetic Foot
Braiki, M., Khalifa, M. A., Faidi, B., Ghannouchi, M., & Derbel, F. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.94331 · Cited by 2
Strategies for the prevention or reversal of neuropathy
Zilliox, L. A., Chandrasekaran, K., & Russell, J. W. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-820669-0.00016-5 · Cited by 2
Diabetic neuropathy: Current issues in diagnosis and prevention
Spallone, V. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-88426-6.00016-6 · Cited by 2
Pop‐Busui, R., Rosin, S. P., Butera, N. M., Krause-Steinrauf, H. J., Assi, H. A., Garg, R., Inzucchi, S. E., Katona, A. M., McGill, J. B., Mudaliar, S. R. D., et al. (2025) · Diabetes Care · doi:10.2337/dc25-1087 · Cited by 2
Self-citationRetinopathy, Neuropathy, and Foot Care
(2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch19 · Cited by 1
Differential diagnosis of polyneuropathies in diabetes mellitus
Khramilin, V. N. (2021) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2021-12-256-265 · Cited by 1
Yip, M. Y. T., Wang, Z., Gutiérrez, L., Foo, V. H. X., Lim, J., Lim, G., Gunasekeran, D. V., Wong, T. Y., & Ting, D. S. W. (2022) · Royal Society of Chemistry eBooks · doi:10.1039/9781839165498-00305 · Cited by 1
Diabetes and the Nervous System
Vinik, A. I., CASELLINI, C. M., & Neumann, S. A. (2018) · Endocrinology · doi:10.1007/978-3-319-44433-8_10 · Cited by 1
Raissi, G. R., Hamze, M., Alemrajabi, M., & Sajadi, S. (2022) · Obesity Medicine · doi:10.1016/j.obmed.2022.100396 · Cited by 1
Response to: ‘Methylcobalamine is effective in peripheral neuropathies’
Thakkar, K. B., & Billa, G. (2015) · European Journal of Clinical Nutrition · doi:10.1038/ejcn.2014.283
EFFECTIVENESS OF ELECTROTHERAPY IN CHRONIC PAINFUL DIABETIC NEUROPATHY
Shanmugam, A., Jayapackiam, T., Bronson, S. C., Nandhini, L., & Shantharam, D. (2017) · Journal of Evolution of Medical and Dental Sciences · doi:10.14260/jemds/2017/286
Metformin: Pharmacogenetics and metabolic effects
Out (2018) · Research Publications (Maastricht University) · doi:10.26481/dis.20180709mo
Peripheral neuropathy in diabetes mellitus
Stirban, A. O. (2015) · doi:10.4155/fseb2013.13.25
Prediction model of physical activity level and diabetes mellitus based on artificial neural network
Wang, Y., xiaofei, L., Zhang, P., Li, J., & yiting, W. (2021) · Journal of Physics Conference Series · doi:10.1088/1742-6596/1848/1/012104
Epigenetic Landscape of Pain in Diabetic Neuropathy
Kwiatkowska, K. M. (2021) · AMS Dottorato Institutional Doctoral Theses Repository (University of Bologna) · doi:10.6092/unibo/amsdottorato/9577
Cardiovascular Pathology – a Factor of the Adverse Course of Diabetic Polyneuropathy
CHUPRYNA, G., Dubynetska, V. M., & Kachur, K. (2021) · Family Medicine · doi:10.30841/2307-5112.2-3.2021.240761
“The incidence of DP is higher in people with type 2 DM (6,100 per 100,000 people per year) than in people with type 1 DM (2,800 per 100,000 people per year) [2, 11, 14, 15].”
BackgroundDiabetes and the Nervous System
Vinik, A. I., CASELLINI, C. M., & Neumann, S. A. (2019) · Endocrinology · doi:10.1007/978-3-319-27316-7_10-3
Diabetes and the Nervous System
Vinik, A. I., CASELLINI, C. M., & Neumann, S. A. (2018) · Endocrinology · doi:10.1007/978-3-319-27316-7_10-2
Prevention of Major Amputation secondary to Diabetes-related Foot Disease
Hayes, J. M. (2022) · Cronfa (Swansea University) · doi:10.23889/suthesis.60123
A Brief Review on the Association of Prolonged Metformin Therapy and Vitamin B12 Deficiency
Babu, R., Mohamed Yasir., H., & Babu, B. (2023) · International Journal of Research and Review · doi:10.52403/ijrr.20230652
刘, 震. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.143748
Rahmanian, M., Yaghoobpoor, S., Deravi, N., Poudineh, M., Mirmohammadali, S. N., Kashanizadeh, M. G., Poopak, A., Faridzadeh, A., Erabi, G., Amouei, E., et al. (2024) · Neurology Asia · doi:10.54029/2024utt
“47 A meta-analysis study by Greco et al. 39 They showed that DPN prevalence was significantly higher in T2DM patients with NAFLD.”
BackgroundDistribution Patterns of Neurography in Diabetic NeuropathyPreprint
Owolabi, L. F., & Alghamdi, M. A. A. (2024) · Research Square · doi:10.21203/rs.3.rs-4582287/v1
Sanders, W. M. (2024) · Deep Blue (University of Michigan) · doi:10.7302/24100
Srisakthi, J., Annadurai, D., & Ganesh Kumar, P. (2025) · International Surgery Journal · doi:10.18203/2349-2902.isj20250140
Detection and Treatment of Chronic Complications
Soe, K. K., & Gunasekaran, U. (2020) · American Diabetes Association eBooks · doi:10.2337/9781580406314.ch05
Idiaquez, J. F., Perkins, B. A., & Bril, V. (2025) · Elsevier eBooks · doi:10.1016/b978-0-323-95702-1.00472-3
Self-citationGaliero, R., Rezki, A., Simeon, V., Beccia, D., Alfano, M., Caturano, A., Sasso, F. C., & Valensi, P. E. (2025) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2025.109107
Laugesen, A. K., Køhler, E., Buhl, C. S., & Brincks, J. (2025) · Clinical Rehabilitation · doi:10.1177/02692155251397583
“5 It involves damage to sensory and motor nerves, leading to symptoms such as neuropathic pain, numbness, and reduced balance control due to diminished proprioception and delayed re fl exes.”
Shi, L., Wei, H., Zhang, T., Li, Z., Chi, X., Liu, D., Chang, D., Zhang, Y., Wang, X., & Zhao, Q. (2021) · Figshare · doi:10.6084/m9.figshare.16551037
Updates in Management of Diabetic Peripheral Neuropathy
Day, A. J. (2023) · eScholarship (California Digital Library)
Nerve Under Siege: Managing Diabetic Neuropathy and Pain
Alom, S., Ali, F., Abubakar, M., Yogi, S., & Bhat, H. R. (2026) · Springer eBooks · doi:10.1007/978-981-95-8946-3_3
SLOAN, G. P., Azmi, S., Eid, S., Ferdousi, M., Røikjer, J., Κender, Ζ., D’Onofrio, L., Karlafti, E., Callaghan, B. C., & Perkins, B. A. (2026) · Journal of the Peripheral Nervous System · doi:10.1111/jns.70124 · Cited by 2
Self-citationChoe, H. J., Koo, B. K., Hong, Y., Kim, N. H., Moon, J. S., Lee, Y., Cho, H., Kwak, S. H., Lim, S. K., Kim, D.-L., et al. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113388
Hsu, C.-Y., & Lee, I. (2026) · Medical Sciences · doi:10.3390/medsci14060605
“Insulin and oral insulin secretagogues have been reported to increase the risk of DPN [49].”
Ma, J., Tang, Y., Xie, Q., Xu, S., Shen, S., Zhang, Y., Zhang, F., Li, J., Jiang, H., Zhong, X., et al. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1946996
“Robust clinical evidence con fi rms its independent correlation with neuropathy severity, and the BARI 2D trial demonstrated that IR-improving strategies (using insulin sensitizers) reduce neuropathy incidence compared with insulin-replacement therapy (51).”
Shaik Naveed, V. S., Sakthivel, V., Prabakaran, V., & Ganesan, V. (2024) · Journal of chemical health risks
Sheehan, A. L., O’Malley, J. M., GUNAWAN, S., Laynor, G., Nicholson, A., Illenberger, N., & Natarajan, S. (2026) · Journal of General Internal Medicine · doi:10.1007/s11606-026-10801-z
Metadata
- Authors
- Pop-Busui, R., Lu, J., Brooks, M. M., Albert, S., Althouse, A. D., Escobedo, J., Green, J., Palumbo, P., Perkins, B. A., Whitehouse, F., Jones, T. L. Z., & for the BARI 2D Study Group
- Affiliations
- Department of Internal Medicine, Division of Metabolism, Endocrinology and Diabetes, University of Michigan, Ann Arbor, Michigan
- University of Pittsburgh (US)
- Saint Louis University (US)
- Mexican Social Security Institute (MX)
- Duke University (US)
- Mayo Clinic (US)
- University of Toronto (CA)
- Henry Ford Health (US)
- National Institutes of Health (US)
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2013-09-14
- Volume
- 36
- Issue
- 10
- Pages
- 3208-3215
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3781573
- OpenAlex
- W2126800252
- Cited by
- 167
- References
- 38
- Citations by year
- 2026: 7 · 2025: 12 · 2024: 15 · 2023: 13 · 2022: 12 · 2021: 24 · 2020: 25 · 2019: 11 · 2018: 21 · 2017: 5 · 2016: 8 · 2015: 7 · 2014: 7
- FWCI
- 5.77
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- American Diabetes Association
- Bristol-Myers Squibb
- Eli Lilly and Company
- Amylin Pharmaceuticals
- GlaxoSmithKline
- Sanofi
- Medtronic
- European Foundation for the Study of Diabetes
- Novo Nordisk
- National Institutes of Health
- National Heart, Lung, and Blood Institute (U01HL063804, U01HL061748, U01HL061744, U01HL061746)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK020572)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- diabetic peripheral neuropathy, glycemic control, insulin sensitizers, insulin therapy, type 2 diabetes, BARI 2D trial, neuropathy incidence, neuropathy prevalence, sex differences, Michigan Neuropathy Screening Instrument, coronary artery disease
- MeSH terms
- Aged, Blood Glucose, Diabetes Mellitus, Type 2, Diabetic Neuropathies, Female, Humans, Hypoglycemic Agents, Male, Middle Aged, Peripheral Nervous System Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.